1175 related articles for article (PubMed ID: 16107909)
1. Drug-induced long QT syndrome and torsade de pointes.
Morissette P; Hreiche R; Turgeon J
Can J Cardiol; 2005 Aug; 21(10):857-64. PubMed ID: 16107909
[TBL] [Abstract][Full Text] [Related]
2. Drug-induced long QT and torsade de pointes: recent advances.
Kannankeril PJ; Roden DM
Curr Opin Cardiol; 2007 Jan; 22(1):39-43. PubMed ID: 17143043
[TBL] [Abstract][Full Text] [Related]
3. QT interval prolongation, torsade de pointes and renal disease.
Patanè S; Marte F; Di Bella G; Currò A; Coglitore S
Int J Cardiol; 2008 Nov; 130(2):e71-3. PubMed ID: 18255176
[TBL] [Abstract][Full Text] [Related]
4. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors.
Zeltser D; Justo D; Halkin A; Prokhorov V; Heller K; Viskin S
Medicine (Baltimore); 2003 Jul; 82(4):282-90. PubMed ID: 12861106
[TBL] [Abstract][Full Text] [Related]
5. Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes.
Sala M; Coppa F; Cappucciati C; Brambilla P; d'Allio G; Caverzasi E; Barale F; De Ferrari GM
Curr Opin Investig Drugs; 2006 Mar; 7(3):256-63. PubMed ID: 16555686
[TBL] [Abstract][Full Text] [Related]
6. QT interval prolongation and torsade de pointes.
Patanè S; Marte F; Di Bella G
Int J Cardiol; 2009 Jan; 131(2):e51-3. PubMed ID: 17689729
[TBL] [Abstract][Full Text] [Related]
7. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G
Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632
[TBL] [Abstract][Full Text] [Related]
8. The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias.
Topilski I; Rogowski O; Rosso R; Justo D; Copperman Y; Glikson M; Belhassen B; Hochenberg M; Viskin S
J Am Coll Cardiol; 2007 Jan; 49(3):320-8. PubMed ID: 17239713
[TBL] [Abstract][Full Text] [Related]
9. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
Abi-Gerges N; Philp K; Pollard C; Wakefield I; Hammond TG; Valentin JP
Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
[TBL] [Abstract][Full Text] [Related]
10. Torsade de pointes: the clinical considerations.
Gowda RM; Khan IA; Wilbur SL; Vasavada BC; Sacchi TJ
Int J Cardiol; 2004 Jul; 96(1):1-6. PubMed ID: 15203254
[TBL] [Abstract][Full Text] [Related]
11. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.
Drici MD; Clément N
Drug Saf; 2001; 24(8):575-85. PubMed ID: 11480490
[TBL] [Abstract][Full Text] [Related]
12. Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes?
Samuelov-Kinori L; Kinori M; Kogan Y; Swartzon M; Shalev H; Guy D; Ferenidou F; Mashav N; Sadeh B; Atzmony L; Kliuk-Ben-Basat O; Steinvil A; Justo D
J Electrocardiol; 2009; 42(4):353-357.e1. PubMed ID: 19261294
[TBL] [Abstract][Full Text] [Related]
13. Drug-induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: the case of antipsychotics.
Calderone V; Testai L; Martinotti E; Del Tacca M; Breschi MC
J Pharm Pharmacol; 2005 Feb; 57(2):151-61. PubMed ID: 15720777
[TBL] [Abstract][Full Text] [Related]
14. Long QT syndrome caused by noncardiac drugs.
Viskin S; Justo D; Halkin A; Zeltser D
Prog Cardiovasc Dis; 2003; 45(5):415-27. PubMed ID: 12704598
[TBL] [Abstract][Full Text] [Related]
15. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
Ahmad K; Dorian P
Europace; 2007 Sep; 9 Suppl 4():iv16-22. PubMed ID: 17766320
[TBL] [Abstract][Full Text] [Related]
16. Gender differences in the proarrhythmic potential of QT-prolonging drugs.
Wolbrette D
Curr Womens Health Rep; 2002 Apr; 2(2):105-9. PubMed ID: 12116598
[TBL] [Abstract][Full Text] [Related]
17. Novel therapeutics for treatment of long-QT syndrome and torsade de pointes.
Khan IA; Gowda RM
Int J Cardiol; 2004 May; 95(1):1-6. PubMed ID: 15159030
[TBL] [Abstract][Full Text] [Related]
18. Citalopram induced torsade de pointes, a rare life threatening side effect.
Kanjanauthai S; Kanluen T; Chareonthaitawee P
Int J Cardiol; 2008 Dec; 131(1):e33-4. PubMed ID: 17919753
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of uncorrected versus corrected QT interval for prediction of torsade de pointes associated with intravenous haloperidol.
Tisdale JE; Kovacs R; Mi D; McCabe GP; Cariera BL; Sharma N; Rosman H
Pharmacotherapy; 2007 Feb; 27(2):175-82. PubMed ID: 17253907
[TBL] [Abstract][Full Text] [Related]
20. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?
Mayet S; Gossop M; Lintzeris N; Markides V; Strang J
Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]